1. Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD

   • Helen J. McBride
   • Ashley Frazer-Abel
   • Jennifer Liu

   Original Article Open access 10 October 2023 Pages: 3299 - 3309

   

2. Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis

   • Takashi Koike
   • Katsuhiro Miura
   • Shin Aizawa

   Original Article 01 September 2023 Pages: 3311 - 3323

   

3. An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis

   • Ying Xu
   • Wenting Li
   • Xiaoping Huang

   Original Article 03 October 2023 Pages: 3325 - 3333

   

4. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease

   • Jia‑wen Dai
   • He Lin
   • Xin-xin Cao

   Original Article 03 November 2023 Pages: 3335 - 3343

   

5. E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia

   • Yanfeng Liu
   • Peng Chen
   • Xiaoping Chen

   Original Article 04 September 2023 Pages: 3345 - 3355

   

6. miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia

   • Huibo Li
   • Jinxiao Hou
   • Shengjin Fan

   Original Article 19 September 2023 Pages: 3357 - 3367

   

7. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study

   • Guangyang Weng
   • Jingya Huang
   • Xin Du

   Original Article 18 September 2023 Pages: 3369 - 3381

   

8. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial

   • Steffen Koschmieder
   • Susanne Isfort
   • Heike L. Pahl

   Original Article Open access 04 October 2023 Pages: 3383 - 3399

   

9. Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy

   • Hongwei Tang
   • Ying Chen
   • Kang Zhou

   Original Article 25 October 2023 Pages: 3401 - 3412

   

10. Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective study

    • Hurong Lai
    • Yansong Tu
    • Jian Li

    Original Article Open access 01 November 2023 Pages: 3413 - 3426

    

11. A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia

    • Rodrick Babakhanlou
    • Marc-Elie Nader
    • Yesid Alvarado

    Original Article 15 September 2023 Pages: 3427 - 3430

    

12. Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children’s Cancer Group study ALL-2015

    • Kangkang Liu
    • Jingbo Shao
    • Hui Jiang

    Original Article 08 August 2023 Pages: 3431 - 3444

    

13. Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma

    • Patricia Johansson
    • Stefan Alig
    • Andreas Hüttmann

    Original Article Open access 11 August 2023 Pages: 3445 - 3455

    

14. High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy

    • Marcella Visentini
    • Andrea Pica
    • Alessandro Pulsoni

    Original Article Open access 31 August 2023 Pages: 3457 - 3463

15. Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China

    • Xiaosheng Li
    • Qianjie Xu
    • Haike Lei

    Original Article Open access 24 August 2023 Pages: 3465 - 3475

    

16. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma

    • Osama Abd El Hameed Ebid
    • Lobna R. Ezz El Arab
    • Menha Swellam

    Original Article Open access 02 September 2023 Pages: 3477 - 3488

    

17. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies

    • Taku Kikuchi
    • Nobuhiro Tsukada
    • Tadao Ishida

    Original Article 05 September 2023 Pages: 3489 - 3497

    

18. c-Myc inhibits LAPTM5 expression in B-cell lymphomas

    • Yanqing Zhang
    • Xin Zhang
    • Duonan Yu

    Original Article 15 September 2023 Pages: 3499 - 3513

    

19. The experience of diagnosis and treatment for TAFRO syndrome

    • Xiaolong Wu
    • Xudong Zhang
    • Mingzhi Zhang

    Original Article 15 September 2023 Pages: 3515 - 3520

    

20. Clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type

    • Tianzi Xu
    • Yi Li
    • Yongchang Wei

    Original Article 13 September 2023 Pages: 3521 - 3532

    

21. Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group

    • Ronakrit Thanhakun
    • Kitsada Wudhikarn
    • on behalf of the Thai Lymphoma Study Group

    Original Article 18 September 2023 Pages: 3533 - 3541

    

22. Predictors of health-related quality of life of the patients treated for MM: the first study in the Palestinian healthcare system

    • Ramzi Shawahna
    • Riad Amer
    • Mohmmad Zain-Aldain

    Original Article 06 October 2023 Pages: 3543 - 3554

23. The association of intestinal microbiota diversity and outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis

    • Shufen Wang
    • Xiaoyan Yue
    • Haowen Xiao

    Original Article 28 September 2023 Pages: 3555 - 3566

    

24. Effectiveness of single-dose 6 mg pegfilgrastim in mobilizing peripheral blood stem cells in allogeneic hematopoietic cell transplantation donors

    • Junjie Cao
    • Aizhen Li
    • Peipei Ye

    Original Article 29 September 2023 Pages: 3567 - 3573

    

25. IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy

    • Xindi Wang
    • Chenggong Li
    • Yu Hu

    Original Article Open access 09 October 2023 Pages: 3575 - 3585

    

26. Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use

    • Flora Kovacsova
    • Frantisek Folber
    • Jiri Mayer

    Original Article Open access 03 October 2023 Pages: 3587 - 3591

    

27. Epstein–Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation

    • Jiajia Hu
    • Jie Zhao
    • Shanshan Li

    Original Article 13 October 2023 Pages: 3593 - 3601

    

28. Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms

    • Xinhui Zheng
    • Hongye Gao
    • Mingzhe Han

    Original Article 25 October 2023 Pages: 3603 - 3611

    

29. Validation of venous thromboembolism predictive model in hematologic malignancies

    • Agnerys López Sacerio
    • Mara Caridad Tejeda Ramón
    • Anna Falanga

    Original Article 02 October 2023 Pages: 3613 - 3620

    

30. Discovering a novel pathogenic CDAN1 variant using exome sequencing and bioinformatics analysis

    • Ling-Hu Cai
    • Chuan-Chuan Liu
    • Lu-Feng Li

    Letter to the Editor 21 August 2023 Pages: 3621 - 3623

    

31. Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report

    • Changyou Li
    • Xiyuan Zhang
    • Peng Zhao

    Letter to the Editor 22 August 2023 Pages: 3625 - 3627

    

32. A case report of dyskeratosis congenita caused by a novel TERC mutation

    • Weiru Liang
    • Lei Ye
    • Fengkui Zhang

    Letter to the Editor 09 September 2023 Pages: 3629 - 3630

    

33. Clonal hematopoiesis with TET2 mutations spawning synchronous primary central nervous system lymphoma and myelodysplastic syndrome

    • Hannes Treiber
    • Christina Ganster
    • Gerald G. Wulf

    Letter to the Editor Open access 13 September 2023 Pages: 3631 - 3633

    

34. Diagnosis of sinusoidal obstruction syndrome: can biopsy be the key?

    • Oliver Kriege
    • Andreas Kreft
    • Eva-Maria Wagner-Drouet

    Letter to the Editor Open access 23 September 2023 Pages: 3635 - 3637

    

35. Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians

    • Martin Philipp Dieterle
    • Gila Mostufi-Zadeh-Haghighi
    • Monika Engelhardt

    Letter to the Editor Open access 15 September 2023 Pages: 3639 - 3641

    

36. Clonal myeloid disorders following CAR T-cell therapy

    • Michael Andersen Jr
    • Poorva Bindal
    • Rushad Patell

    Letter to the Editor 26 September 2023 Pages: 3643 - 3645

    

37. The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia

    • Ozlem Candan
    • Derya Demirtas
    • Tayfur Toptas

    Letter to the Editor 20 September 2023 Pages: 3647 - 3648

38. Multiple myeloma relapse as extramedullary plasmacytoma of the penis

    • Henrique Coelho
    • Margarida Badior
    • Márcio Tavares

    Letter to the Editor 25 September 2023 Pages: 3649 - 3651